DENTSPLY SIRONA (XRAY) CAO granted RSUs and stock options through 2029 vesting
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
DENTSPLY SIRONA Inc. executive Kevin Czerney, VP and Chief Accounting Officer, reported equity awards granted on March 4, 2026. He received stock options for 10,400 shares and a grant of 13,690 shares of common stock.
The common stock award consists entirely of restricted stock units that vest in one-third installments over three years, ending March 4, 2029. The stock options also vest in one-third annual increments through March 4, 2029 and carry an exercise price equal to 110% of the closing share price on the grant date.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Czerney Kevin
Role
VP, Chief Accounting Officer
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 10,400 | $0.00 | -- |
| Grant/Award | Common Stock | 13,690 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 10,400 shares (Direct);
Common Stock — 41,268.908 shares (Direct)
Footnotes (1)
- Award consists entirely of Restricted Stock Units (RSUs) which vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029. Stock options vest in annual one-third (1/3) increments over a three-year (3) period ending March 4, 2029, with an exercise price equal to 110% of the closing price of the Issuer's common stock as of the date of grant.
FAQ
What insider transactions did DENTSPLY SIRONA (XRAY) report for Kevin Czerney?
Kevin Czerney received equity awards consisting of stock options and restricted stock units. The filing shows 10,400 stock options and 13,690 shares of common stock granted, all reported as acquisitions rather than open‑market purchases or sales, reflecting compensation rather than trading activity.
How many DENTSPLY SIRONA (XRAY) stock options were granted to Kevin Czerney?
Kevin Czerney was granted stock options covering 10,400 shares. According to the filing, these options vest in equal one‑third installments over three years, ending March 4, 2029, and have an exercise price set at 110% of the common stock’s closing price on the grant date.
What restricted stock unit (RSU) grant did Kevin Czerney receive from DENTSPLY SIRONA (XRAY)?
Kevin Czerney received an award of 13,690 shares of common stock in the form of restricted stock units. The RSUs vest in one‑third annual installments over a three‑year period ending March 4, 2029, aligning his compensation with multi‑year company performance and retention goals.
How do Kevin Czerney’s new DENTSPLY SIRONA (XRAY) equity awards vest over time?
Both the RSUs and stock options vest in equal one‑third installments over three years. Vesting runs through March 4, 2029, meaning portions of the 13,690 RSUs and 10,400 options become exercisable or deliver shares annually, supporting long‑term executive incentive alignment.
What is the exercise price structure of Kevin Czerney’s DENTSPLY SIRONA (XRAY) stock options?
The stock options granted to Kevin Czerney have an exercise price equal to 110% of the common stock’s closing price on the grant date. This premium pricing typically requires future stock price appreciation before the options provide intrinsic economic value to the holder.